Suchen
Zymeworks Inc
ZYMEZur Watchlist hinzufügen
25.720USD
-0.420-1.61%
Handelsschluss 07/01, 16:00（ET）Kurse um 15 Minuten verzögert
1.84BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Zymeworks Inc Unternehmen
Zymeworks Inc. is a global clinical-stage biotechnology company. The Company is developing a diverse pipeline of multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases such as cancer, autoimmune and inflammatory diseases (AIID). The Company engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s Azymetric technology. It has entered into separate agreements with BeiGene, Ltd. and Jazz Pharmaceuticals Ireland Limited, granting each exclusive rights to develop and commercialize zanidatamab in different territories. It is advancing a pipeline of wholly-owned product candidates, leveraging its expertise in both antibody-drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. The Company has two clinical-stage product candidates: ZW171 and ZW191. Its preclinical product candidates include ZW251, ZW220, ZW209, and ZW1528.
Zymeworks Inc Informationen
BörsenkürzelZYME
Name des UnternehmensZymeworks Inc
IPO-datumJun 24, 2019
CEOGalbraith (Kenneth H)
Anzahl der mitarbeiter280
WertpapierartOrdinary Share
GeschäftsjahresendeJun 24
Addresse108 Patriot Drive, Suite A
StadtMIDDLETOWN
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl19709
Telefon13022748744
Websitehttps://www.zymeworks.com/
BörsenkürzelZYME
IPO-datumJun 24, 2019
CEOGalbraith (Kenneth H)
Führungskräfte von Zymeworks Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Kenneth H. (Ken) Galbraith
Mr. Kenneth H. (Ken) Galbraith
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Dr. Susan M. (Sue) Mahony, Ph.D.
Dr. Susan M. (Sue) Mahony, Ph.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. Kelvin M. Neu ,M.D.
Dr. Kelvin M. Neu ,M.D.
Independent Director
Independent Director
--
--
Dr. Paul A. Moore, Ph.D.
Dr. Paul A. Moore, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Carlos E. Campoy
Mr. Carlos E. Campoy
Independent Director
Independent Director
--
--
Dr. Alessandra Cesano, M.D., Ph.D.
Dr. Alessandra Cesano, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Scott Platshon
Mr. Scott Platshon
Acting Chief Investment Officer
Acting Chief Investment Officer
--
--
Ms. Leone D. Patterson, CPA
Ms. Leone D. Patterson, CPA
Chief Financial Officer, Chief Business Officer, Executive Vice President
Chief Financial Officer, Chief Business Officer, Executive Vice President
--
--
Dr. Jeffrey Smith, M.D.
Dr. Jeffrey Smith, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
--
--
Mr. Oleg Nodelman
Mr. Oleg Nodelman
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Kenneth H. (Ken) Galbraith
Mr. Kenneth H. (Ken) Galbraith
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Dr. Susan M. (Sue) Mahony, Ph.D.
Dr. Susan M. (Sue) Mahony, Ph.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. Kelvin M. Neu ,M.D.
Dr. Kelvin M. Neu ,M.D.
Independent Director
Independent Director
--
--
Dr. Paul A. Moore, Ph.D.
Dr. Paul A. Moore, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Carlos E. Campoy
Mr. Carlos E. Campoy
Independent Director
Independent Director
--
--
Dr. Alessandra Cesano, M.D., Ph.D.
Dr. Alessandra Cesano, M.D., Ph.D.
Independent Director
Independent Director
--
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Zymeworks Inc?
Die fünf größten Anteilseigner von Zymeworks Inc sind: Mr. Kenneth H. (Ken) Galbraith